Nick James, a 45-year-old British cabinetmaker, watched his mother die of cancer and then saw his brother develop an intestinal tumor. When genetic tests confirmed that he carried the Lynch syndrome gene — a mutation that drastically multiplies the risk of colorectal cancer — he became the first enrollee in a clinical trial led by Professor John Burn: a daily dose of aspirin as a preventive shield. Ten years later, James has not developed the disease. The mechanism behind the effect points to two pathways: aspirin would inhibit the Cox-2 enzyme, involved in the uncontrolled growth of cells, and block thromboxane A2, a clotting substance that could hide cancer cells from the immune system. By blocking it, malignant cells would be exposed and eliminated more effectively. A second trial, led by the Swedish researcher Martling and published in September 2025, confirmed the results with even lower doses — between 75 and 100 mg — and with minimal adverse effects. The impact was so immediate that since January 2026, Sweden has already offered preventive aspirin to all patients with intestinal cancer who have those genetic mutations.